Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Abeta in plasma of patients with Alzheimer's disease
2011 (English)In: Neurobiology of Aging, ISSN 0197-4580, E-ISSN 1558-1497, Vol. 32, no 8, 1379-1387 p.Article in journal (Refereed) Published
In the present work, we investigated the level of IgM autoantibodies directed against different Abeta epitopes as potential diagnostic biomarker for Alzheimer's disease (AD). Anti-Abeta autoantibody levels were measured in 75 plasma samples from patients with AD, individuals with mild cognitive impairment (MCI), and healthy age- and sex-matched controls (HC). To validate the presence of anti-Abeta IgMs, pooled plasma samples were subjected to gel-filtration analysis. The mean level of pGluAbeta-IgM (N-terminal truncated starting at position three with pyroglutamate) was significantly decreased in AD patients as compared to HC. In the group of MCI patients there was a significant positive correlation between pGluAbeta-IgM and cognitive decline analyzed by MMSE (rho=0.58, d.f.=13, p=0.022). These observations indicate that the level of IgM autoantibodies against pGluAbeta is a promising plasma biomarker for AD and correlates with the cognitive status of individuals at risk to develop AD.
Place, publisher, year, edition, pages
2011. Vol. 32, no 8, 1379-1387 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-123189DOI: 10.1016/j.neurobiolaging.2009.08.011PubMedID: 19781815OAI: oai:DiVA.org:uu-123189DiVA: diva2:312893